SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bent N)
 

Sökning: WFRF:(Bent N) > (2015-2019) > Cholesterol, choles...

  • Borgquist, SigneLund University,Lunds universitet,Kliniska Vetenskaper, Helsingborg,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Clinical Sciences, Helsingborg,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund (författare)

Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • 2017
  • 10 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:4781baf3-1ccd-458d-8ffd-38c214b570de
  • https://lup.lub.lu.se/record/4781baf3-1ccd-458d-8ffd-38c214b570deURI
  • https://doi.org/10.1200/JCO.2016.70.3116DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol metabolite 27-hydroxycholesterol. The impact of endocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended effect of aromatase inhibitors. Patients and Methods The Breast International Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-positive invasive breast cancer from 1998 to 2003. Systemic levels of total cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years. Cumulative incidence functions were used to describe the initiation of CLM in the presence of competing risks. Marginal structural Cox proportional hazards modeling investigated the relationships between initiation of CLM during endocrine therapy and outcome. Three time-to-event end points were considered: disease-freesurvival, breast cancer-free interval, and distant recurrence-free interval. Results Cholesterol levels were reduced during tamoxifen therapy. Of 789 patients who initiated CLM during endocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy (n = 106). Initiation of CLM during endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI, 0.66 to 0.95; P = .01), breast cancer-free interval (HR, 0.76; 95% CI, 0.60 to 0.97; P = .02), and distant recurrence-free interval (HR, 0.74; 95% CI, 0.56 to 0.97; P = .03). Conclusion Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing breast cancer recurrence in hormone receptor-positive early-stage breast cancer. We recommend that these observational results be addressed in prospective randomized trials.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Giobbie-Hurder, AnitaDana-Farber Cancer Institute (författare)
  • Ahern, Thomas PUniversity of Vermont (författare)
  • Garber, Judy EHarvard Medical School (författare)
  • Colleoni, MarcoEuropean Institute of Oncology (författare)
  • Láng, IstvánNational Institute of Oncology, Budapest (författare)
  • Debled, MarcInstitut Bergoníe (författare)
  • Ejlertsen, BentCopenhagen University Hospital (författare)
  • Von Moos, RogerCantonal Hospital Graubunden (författare)
  • Smith, Ian E.Royal Marsden Hospital, London (författare)
  • Coates, Alan S.University of Sydney (författare)
  • Goldhirsch, AronEuropean Institute of Oncology (författare)
  • Rabaglio, ManuelaBern University Hospital (författare)
  • Price, Karen N.Frontier Science and Technology Research Foundation (författare)
  • Gelber, Richard D.Frontier Science and Technology Research Foundation (författare)
  • Regan, Meredith M.Frontier Science and Technology Research Foundation (författare)
  • Thürlimann, BeatBreast Center St. Gallen (författare)
  • Kliniska Vetenskaper, HelsingborgSektion II (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Oncology35:11, s. 1179-11880732-183X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy